For the first time, the present work proved that IPO7 was a novel oncogene in pancreatic cancer, which exerted its biological function partly via repressing p53, and these results suggested that targeting IPO7 could probably be a promising strategy to treat pancreatic cancer. This evidence concerns the gene TP53 and familial pancreatic carcinoma.